Randomized, controlled trial of intraven
β
Gil I. Wolfe; Richard J. Barohn; Barbara M. Foster; Carlayne E. Jackson; John T.
π
Article
π
2002
π
John Wiley and Sons
π
English
β 80 KB
## Abstract We initiated a randomized, doubleβblinded, placeboβcontrolled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in